BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering
BlossomHill Therapeutics , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).
- BlossomHill Therapeutics , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).
- The prestigious honor recognizes Dr. Cui’s direct role in the innovation of new medicines to fight cancer and address urgent medical needs.
- As Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, Dr. Cui leads the effort to design the novel small molecule drug candidates in the company’s R&D pipeline.
- Prior to BlossomHill, Dr. Cui co-founded Turning Point Therapeutics, Inc., which Bristol Myers Squibb acquired in June 2022 for $4.1 billion.